Here are 1-2 brief analogies to describe Black Titan (BTTC):

• IAC for AI and Web3 companies. (Like IAC, which acquires and grows a portfolio of internet and tech businesses, Black Titan aims to build a portfolio of companies in AI, Web3, and blockchain sectors.)

• Prosus (or Naspers) for early-stage AI and Web3 companies. (Similar to Prosus, a global investment and holding company known for its stakes in internet businesses, Black Titan seeks to acquire and nurture companies in emerging digital technologies.)

• Travel Software Development: This involved creating and marketing software applications specifically tailored for the travel industry.
• Online Travel Services: The company provided internet-based services for facilitating travel bookings and related arrangements.

Upon review, Black Titan (symbol: BTTC) does not appear to be a real, currently trading public company. Searches for this company and stock symbol yield no results on major financial databases or regulatory filings.

As such, it is impossible to identify its major customers or categories of customers, as the company does not exist in the public market.

Brynner Chiam assumed the roles of CEO, Acting CFO, and Director of Black Titan Corporation on October 3, 2025. He previously served as an Independent Director of Titan Pharmaceuticals, Inc. from October 12, 2023, to November 6, 2024. Since November 2020, Mr. Chiam has been the Vice President of Finance and Tax at Black Chamber Management, a shared service company, where he is responsible for managing, planning, and executing financing activities for the company and its clients. From February 2014 to October 2020, he was a Director at Tricor Taxand, a professional tax firm. His prior experience includes managerial roles in business and finance consultancy at companies such as Walton International Property Group (M) Sdn Bhd, OSK Investment Bank Bhd, PricewaterhouseCoopers Human Resource Services Pte Ltd (Singapore), and Brooks Business Consultancy Sdn Bhd. Mr. Chiam is a member of the Chartered Tax Institute of Malaysia and possesses over 20 years of experience as a tax consultant and practitioner. He holds a Bachelor of Business Studies in Accountancy from Massey University in New Zealand.

Firdauz Bin Mokhtar has served as the Chief Executive Officer of Saujana Petroleum Sdn Bhd, an investment holding company with marine operation and maintenance activities, since November 2023. He was the Chief Financial Officer of Data Knights Acquisition, a special purpose acquisition company, from February 2021 until its business combination with OneMedNet in November 2023. Earlier, from January 2020 to January 2021, Mr. Mokhtar was the Senior Vice President of Special Projects in the Group CEO Office at Serba Dinamik Holdings Berhad, where he focused on mergers and acquisitions. He also held the position of Chief Financial Officer at PBJV Group Sdn Bhd from May 2012 to November 2019, overseeing accounting, finance, tax, legal, and company secretarial matters. Mr. Mokhtar is a Certified Public Accountant registered with the Malaysian Institute of Accountants and earned his Bachelor Degree (Honors) in Accountancy from The International Islamic University Malaysia in July 1997.

Avraham Ben-Tzvi is the founder of ABZ Law Office, an Israeli boutique law firm established in January 2017, specializing in corporate & securities laws, commercial law & contracts, and providing outsourced general counsel services for public and private companies. He served as Chief Legal Officer and General Counsel of Purple Biotech Ltd. (formerly Kitov Pharma Ltd.), a clinical-stage company, from November 2015 until April 2020. Prior to that, he was General Counsel and secretary at Medigus Ltd. from April 2014 to November 2015. His career also includes experience as an attorney at a leading international law firm. Before becoming a lawyer, Mr. Ben-Tzvi gained diverse commercial experience in business development roles at global hi-tech firms in the financial services and telecommunications industries, and in finance as a credit officer and corporate treasurer. He has extensive experience in capital markets, corporate law, commercial law, mergers and acquisitions, project finance, venture capital, and private equity, and has represented clients in private placement transactions and listings on the Tel Aviv Stock Exchange and U.S. capital markets. Mr. Ben-Tzvi holds a B.A. in Economics from Yeshiva University and an LLB from Sha'arei Mishpat College of Law.

Gabriel Loh is a Senior Fellow in AMD Research and Advanced Development at Advanced Micro Devices, Inc. His research interests include computer architecture, processor microarchitecture, emerging technologies, and 3D die stacking. He holds a PhD and MS in computer science from Yale University and a BE in electrical engineering from the Cooper Union. Dr. Loh’s previous roles include being an associate professor at the Georgia Institute of Technology, a visiting researcher at Microsoft Research, and a senior researcher at Intel Corporation. He is a key technical leader for AMD's PathForward program, which is part of the U.S. Department of Energy’s Exascale Computing Project. For his contributions to die-stacking technologies in computer architecture, Dr. Loh received the ACM SIGARCH Maurice Wilkes Award in 2018 and was named an ACM Fellow in 2017. He is also the inventor or co-inventor on over 60 granted U.S. patents.

The public company Black Titan (symbol: BTTC) faces several key risks, primarily stemming from its recent strategic pivot and corporate restructuring:

1. High Volatility and Market Risk Associated with Digital Asset Exposure: Black Titan Corporation has recently shifted its focus to a "Digital Asset Treasury Plus (DAT+)" strategy, involving digital asset investments and related initiatives. This pivot exposes the company to the inherent volatility of the digital asset market. The company's stock has demonstrated significant price fluctuations, including a sharp decline following a merger in October 2025 and a substantial surge after the announcement of its crypto treasury strategy in December 2025. Such market sensitivity and the stock trading considerably below its 52-week high highlight the speculative nature and potential for significant price swings tied to its digital asset exposure.
2. Regulatory and Legal Risks in the Digital Asset Space: As Black Titan Corporation increasingly engages with digital assets, it becomes subject to the rapidly evolving and often uncertain regulatory landscape governing cryptocurrencies and blockchain technologies. The company's forward-looking statements acknowledge "regulatory developments" as a risk factor that could materially affect its strategic initiatives and growth plans. Changes in regulations, new legal interpretations, or enforcement actions could impact the value of its digital asset holdings, its operational models, and its ability to execute its DAT+ strategy.
3. Post-Merger Integration Challenges: Black Titan Corporation's current form is a result of a merger completed in October 2025, which included Titan Pharmaceuticals and TalenTec Sdn. Bhd. This merger was immediately followed by a significant decline in Black Titan's stock price, reflecting investor uncertainty and a re-evaluation of the combined entity's value. The company faces the ongoing challenge of effectively integrating the operations of these acquired assets and demonstrating the strategic rationale and expected synergies from the merger to stabilize its market position and regain investor confidence.

• The increasing sophistication and adoption of Decentralized Finance (DeFi) platforms, which offer self-custody and direct asset management without reliance on centralized intermediaries, could erode demand for traditional digital asset trust services.

• The recent entry and rapid growth of spot Bitcoin exchange-traded funds (ETFs) offered by established financial titans such as BlackRock and Fidelity introduce formidable competition with superior brand recognition, distribution networks, and massive capital, potentially capturing significant institutional market share.

Black Titan Corporation (symbol: BTTC) operates in two primary markets: Human Capital Management (HCM) software and the development of therapeutics for chronic diseases.

Human Capital Management (HCM) Software Market

The global Human Capital Management (HCM) market was estimated to be between USD 26.47 billion and USD 31.34 billion in 2024. Projections indicate growth to approximately USD 41.3 billion by 2029 at a CAGR of 8.5%, or to USD 64.97 billion by 2032 with a CAGR of 9.60%. Another estimate puts the market at USD 50.23 billion by 2033, growing at a CAGR of 7.01% from 2025 to 2033.

In the Asia-Pacific region, the HCM software market size is valued at USD 8.87 billion in 2025 and is forecast to reach USD 14.41 billion by 2030, exhibiting a CAGR of 10.20%. Specifically for Malaysia, the Core HR Software Market (a segment of HCM) is anticipated to grow at a CAGR of 9.7% from 2024 to 2030. The broader Southeast Asia human resource software market was estimated at USD 578.4 million in 2024 and is projected to grow at a CAGR of 15% from 2025 to 2030.

Therapeutics for Chronic Diseases Market

Black Titan Corporation, through its merger with Titan Pharmaceuticals, Inc., is also involved in the development of therapeutics. The global Central Nervous System (CNS) therapeutics market, a relevant segment for chronic disease treatments, reached USD 148.7 billion in 2024 and is expected to grow to USD 257.3 billion by 2033, with a CAGR of 5.64% from 2025 to 2033. Other estimates for the global CNS therapeutics market range from USD 163.8 billion in 2025 growing to USD 412.1 billion by 2034 (CAGR of 10.8%), to USD 127.29 billion in 2025 reaching USD 267.62 billion by 2034 (CAGR of 8.64%).

The global biopharmaceutical market, which encompasses a wide range of advanced therapeutics, was valued at USD 326.2 billion in 2024 and is projected to reach USD 664.8 billion by 2033, growing at a CAGR of 8.2% during 2025-2033. Another report indicates the global biopharmaceuticals market was valued at USD 421.58 billion in 2024 and is expected to be worth USD 1,369 billion by 2034, expanding at a CAGR of 12.5% from 2024 to 2034. Furthermore, the global market for chronic disease management therapeutics and device technologies was valued at USD 726.3 billion in 2024 and is projected to reach USD 1.1 trillion by 2029, with a CAGR of 8.1% from 2024 through 2029.

For Black Titan (symbol: BTTC), the expected drivers of future revenue growth over the next 2-3 years are primarily centered around its recently announced strategic shift into the cryptocurrency and blockchain sector. On October 6, 2025, Black Titan unveiled its plan to pursue long-term strategic crypto initiatives, including investments in digital currencies. This new direction follows the company's merger with Titan Pharmaceuticals and TalenTec Sdn. Bhd. on October 1, 2025.

The key drivers of future revenue growth for Black Titan are:

1. Direct Digital Currency Acquisitions: Black Titan intends to build its digital currency portfolio through direct coin acquisitions. This strategy aims to capitalize on the potential appreciation of various cryptocurrencies.
2. Cryptocurrency Mining Operations: The company is exploring engaging in cryptocurrency mining as part of its broader digital currency holding strategy. This would generate revenue through the creation of new digital assets.
3. Fintech Mergers and Acquisitions (M&A): Black Titan plans to expand its presence and portfolio within the digital asset space through fintech-related mergers and acquisitions. These strategic investments and acquisitions could bring in new technologies, services, and associated revenue streams.
4. Leveraging Capital for Crypto Holdings: The company explicitly stated its intention to use debt, equity, and cash flow to fund its crypto holdings. While not a direct revenue generator, this approach enables aggressive expansion into the cryptocurrency market, thereby accelerating the potential for revenue growth from its digital asset investments and operations.

Share Issuance

• Black Titan completed a share consolidation on August 23, 2023, converting 500,000,000 ordinary shares (par value US$0.003 each) into 25,000,000 ordinary shares (par value US$0.06 each).
• As part of the merger with Titan Pharmaceuticals and TalenTec Sdn. Bhd., which became effective on October 1, 2025, each outstanding share of Titan common stock was converted into one ordinary share of Black Titan.
• On July 10, 2023, Black Titan issued a total of 4,549,069 ordinary shares to Jianyu Guo and Tianying Zheng as consideration for mining machines acquired under an Asset Transfer Agreement.

Inbound Investments

• Black Titan issued a Drawdown Notice for $5.5 million in Series A Preferred Shares, which is expected to strengthen its financial position and provide flexibility for future growth.

Outbound Investments

• Effective October 1, 2025, Black Titan completed a major business combination, acquiring Titan Pharmaceuticals and TalenTec Sdn. Bhd., making them wholly owned subsidiaries. This transaction effectively shifted the company's focus from biotechnology to human capital management and technology solutions.
• Black Titan announced plans on October 6, 2025, to explore long-term strategic crypto initiatives, including potential strategic investments in digital currencies, direct coin acquisitions, mining, and fintech-related mergers and acquisitions. The company intends to leverage debt, equity, and cash flow to build crypto holdings.